Latest News

On computed tomography (CT) scans, what has been described as a pattern that is “indeterminate for usual interstitial pneumonia” (iUIP) could be indicative of early idiopathic pulmonary fibrosis (IPF) in certain individuals, with disease progression possibly associated with higher levels of monocytes and neutrophils. These were among the results of...
Phase 1 trial demonstrates encouraging clinical activity of investigational immunotherapy for relapsed or refractory multiple myeloma Novel investigational dual-antigen-targeting immunotherapy binds to B-cell maturation antigen (BCMA) and GPRC5D on myeloma cells, as well as CD3 on T-cells CHICAGO, Ill. — Johnson & Johnson announced initial Phase 1 results of JNJ-79635322 (JNJ-5322), a novel...
Motor and memory training early in life postpones the onset of difficulties in those areas in a mouse model of Rett syndrome, according to a study published today in Nature. Stimulating neurons involved in those skills appears to mimic the effects of training. Mutations in the gene MECP2 cause Rett syndrome, which often overlaps with...
Sugar Land, TX – Obesity is a chronic metabolic disease associated with the development of several other metabolic disease, including cancer. The present study aims to evaluate the eating habits, physical activity, and clinical profiles of colorectal cancer (CRC) patients with overweight/obesity. Methods A cross-sectional study was conducted with data...
Philadelphia – Thanksgiving is often a time for thinking about your belly. For those with an inflammatory bowel diseases like ulcerative colitis, feasting can be associated with stress, even when food isn’t a trigger for the painful symptoms. New research in mice suggests that certain foods – especially those high...
BEERSE, Belgium  – Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the European Commission (EC) has approved an indication extension of DARZALEX® (daratumumab) subcutaneous (SC) formulation in the frontline setting. The approval is for daratumumab SC in combination with bortezomib, lenalidomide, and dexamethasone (daratumumab-VRd) for the treatment...